- Biopharma Companies
Advance the asset. Unlock its potential.
A focused path to U.S. development and your next value-creation milestone.
1–2 yr
Defined path to a value inflection
Oncology
Initial therapeutic-area focus
U.S.
Clinical development & IND
FROM PROMISE TO PROGRESS
Advance the Asset Toward a Near-Term Value Inflection
We help biopharma companies clarify and advance promising assets through focused U.S. clinical development, with an initial focus on oncology and cell therapy. For selected programs, the aim is not open-ended co-development: it is a defined 1–2 year effort, supported by a modest, targeted investment, to reach high-impact milestones that can strengthen valuation and expand strategic options.
U.S. Clinical Development Strategy
Development pathways, program strategy and study planning.
Biometrics, Evidence & AI Strategy
Study design, statistical strategy, endpoints, evidence planning, and AI-enabled approaches to data and decision-making.
Biomarker & Translational Strategy
Patient-selection hypotheses, assay and sample plans, translational endpoints and decision-ready evidence strategy.
Regulatory & IND Strategy
U.S. regulatory pathways, IND readiness and FDA interaction preparation.
Clinical Execution
CRO and vendor strategy, development planning and execution oversight.
Asset & Partnering Strategy
Asset assessment, value-inflection planning, partnering and licensing preparation.
HOW WE WORK WITH BIOPHARMA
From strategic guidance to hands-on asset development.
Engage us for targeted expertise—or partner with us to build and execute a focused U.S. development strategy.
MODEL 01
Advisory
Focused Advisory for U.S. Development Strategy and Execution
For companies with the capital and infrastructure to execute, we provide senior-level expertise across clinical development, biometrics, regulatory strategy, development planning and partnering.
- Clinical Development & Biometrics
- Regulatory & IND Strategy
- Development Planning & Execution
- Business & Partnering Strategy
MODEL 02
Partnership
Focused Investment. Hands-On Leadership. Greater Strategic Optionality.
For selected programs, we make a targeted investment and lead a fit-for-purpose U.S. development team over a defined 1–2 year window. The goal is to reach high-value regulatory and early clinical milestones that can boost asset valuation and expand strategic options—including out-licensing, partnering and follow-on financing.
The objective: use focused capital and hands-on execution to create a meaningful near-term value inflection—not establish an open-ended co-development program.
FROM ASSET TO VALUE INFLECTION
A focused path to
U.S. clinical validation.
For selected assets, we build a fit-for-purpose development plan around clear regulatory, clinical and value-creation milestones.
SelectAssess the Opportunity
Evaluate the asset, existing evidence, U.S. development opportunity, key risks and potential value-creation pathway.
StructureBuild the Development Vehicle
Establish the NewCo structure, capital plan, operating model, development team and program roadmap.
AdvanceMove Into U.S. Development
Drive IND strategy and readiness, coordinate regulatory activities, and execute the initial U.S. clinical plan with fit-for-purpose data and AI-enabled capabilities.
ValidateGenerate U.S. Clinical Evidence
Build initial U.S. patient experience and strengthen the asset’s clinical and development package through biometrics, data intelligence, and AI-enabled approaches.
Create ValueReach a Meaningful Inflection Point
Translate regulatory and clinical progress into a stronger development profile and asset value proposition.
PartnerPrepare for the Next Strategic Opportunity
Support pharma partnering, licensing discussions and other strategic opportunities.
TYPICAL SELECTED-PROGRAM FRAME
1–2 years to defined U.S. regulatory and early clinical milestones.
The plan is designed to strengthen the asset's development profile and partnering position—not simply complete a list of activities.
MORE THAN CONSULTING
Expertise. Execution. Alignment.
Our objective is not another strategy deck. It is to move the asset toward its next meaningful value inflection point.
Advise
Bring the right expertise to critical decisions. Access experienced clinical development, biometrics, regulatory, medical, therapeutic-area, data science, commercial and business expertise.
Build
Assemble the right team around the asset. We rapidly bring together a lean, senior, cross-functional team based on the needs and stage of each program.
Invest & Execute
We invest and lead the team.
For selected assets, we can commit both capital and execution resources—not simply provide recommendations or introductions.